Abiopharma

🔍 Weber Christophe Pierre (Director)

Company: BOSTON SCIENTIFIC CORP (BSX)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 1,767 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,646.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,140 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,786.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,660 shares of Deferred Stock Units (Derivative)
  Date: 2026-05-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,660.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4, F4

Footnotes:

• F1: Grant of restricted stock in lieu of 80% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of approximately $100,000 (representing 80% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.
• F2: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Reflects a value of $64,500 (representing 30% of the amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.
• F3: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
• F4: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $150,500 (representing 70% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.